drugset
drugset / Trial / NCT04363242

A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

NCT04363242 ↗

Phase 1 Unknown 22 enrolled Synermore Biologics Co., Ltd. Synermore Biologics USA Limited · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1 Dose Escalation Trial of SYN125 Single Agent in the Treatment of Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Cancer of the Internal or External Lining of the Body.

Timeline

Start
2020-04-09
Primary completion
2023-07-31
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribaxamase Monoclonal antibody — Intravenous
Subject SYN125 Unknown — Intravenous

Indications

carcinoma